MedPath

A prospective, open label, single arm post-market study to assess effectiveness and safety of the base composition bath salt („Basis-Zusammensetzung Badesalz) in healthy subjects

Phase 4
Conditions
Healthy Subjects
Registration Number
DRKS00017458
Lead Sponsor
Alexander Weltecke GmbH & Co. KG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
51
Inclusion Criteria

1) Male or female aged = 18 years on the day of screening
2) Subjects able to understand the informed consent and willing to participate as evidenced by providing informed consent.
3) Signed Informed Consent
4) Subjects able and willing to attend all scheduled visits and comply with all study procedures

Exclusion Criteria

1) Known hypersensitivity to a component of the base composition bath salt
2) Open wounds
3) Active infections
4) Severe generalized disease resulting in a life expectancy shorter than 3 months
5) Pregnant or breast-feeding women
6) Women of childbearing potential without effective contraception
7) Alcohol- or drug abuse
8) Subjects with psychiatric disorders influencing their judgement or autonomy
9) Inability or unwillingness to understand or comply with required study procedures
10) Subjects who are not suitable for the study based on the principal investigator’s evaluation
11) Subjects who are financially or otherwise dependent on the principal investigator or sponsor.
12) Subjects who are imprisoned or have been institutionalized for medical reasons

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effectiveness -<br>Increase in wellbeing will be assessed with a questionnaire before and after treatment
Secondary Outcome Measures
NameTimeMethod
Safety-<br>Safety will be assessed by measuring the incidence and prevalence of adverse events throughout the study.<br>Effectiveness-<br>Skin smoothness will be assessed before and after treatment by visual assessment and measured using a Sebumeter®<br>Transepidermal water loss (TEWL) will be measured before and after treatment using a Tewameter®<br>Skin pH will be measured before and after treatment using a skin pH meter<br>
© Copyright 2025. All Rights Reserved by MedPath